Financial calendar 2020
Nov 1, 2019
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule.
Read moreMajor shareholder announcement
Oct 2, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of October 1, 2019 holds a total 998,962 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of October 1, 2019 controls 7.74% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
Sep 17, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, has been invited to participate in a meeting hosted by the National Organization for Rare Disorders (NORD) and the Critical Path Institute (C-PATH) to launch their joint initiative: the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP). Funded by the US Food and Drug Administration (FDA), the goal of RDCA-DAP is to accelerate the process of moving therapies from bench to bedside for rare diseases.
Orphazyme cmo to speak at fda funded rare disease...
Read moreOrphazyme announces Interim Report First Half 2019
Aug 28, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights.
Orphazyme announces interim report first half 2019
Interim report first half 2019
Read moreOrphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital
Aug 27, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has entered into a structured debt facility (Loan Agreement) with Kreos Capital VI (UK) Limited (Kreos) to secure funding of EUR 9 million. Orphazyme plans to draw down the loan on September 1, 2019. Proceeds from the loan will be used to fund the on-going preparations for filing of arimoclomol in the US and Europe, commercial planning, and for general corporate purposes.
Orphazyme strengthens balance sheet with eur 9 milli
Read moreOrphazyme Interim Report First Half 2019 Presentation
Aug 21, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Interim Report First Half 2019. The presentation will be followed by a Q&A session.
Orphazyme interim report first half 2019 presentation
Read moreMajor shareholder announcement
Aug 5, 2019
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of 2 August 2019 holds a total 1,022,154 shares in the Company, corresponding to 5.11% of the share capital and that Danske Bank as of 2 August 2019 controls 7.86% of the voting rights in the Company.
Orphazyme major shareholder announcement
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 29, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares
Read moreNew phantom share-based incentive program
Jul 29, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a four-year phantom share-based incentive program in July 2019 for, in general, all employees other than the Executive Management team (the “Program”).
Phantom share based incentive program
Read moreNew share-based incentive program
Jul 29, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a new share-based incentive program (the “LTIP”). The LTIP has been implemented in accordance with Orphazyme’s Remuneration Policy, including the guidelines for incentive pay adopted at Orphazyme’s annual general meeting on March 27, 2019.
New share based incentive program
Read more